Mednet Logo
HomeRadiation Oncology
Radiation Oncology

Radiation Oncology

Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.

Recent Discussions

Do you constrain heterogeneity or hotspots when delivering spine SBRT for bone metastases?

4
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Memorial Sloan Kettering Cancer Center

We treat bone and spine mets "SRS" style which means accepting high hot spots (130%) within the GTV to allow for steeper dose fall offs just outside the target and hence lower normal tissue doses...

How do you approach a patient with stage IIA non-small cell lung cancer who received SBRT?

5
3 Answers

Mednet Member
Mednet Member
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

Well, this is a very challenging question that certainly has come up in discussions at times over the years and I could conclude with a very simple answer: No or could offer a more twisted answer arriving at the same response- just for the fun of it, let’s do the latter.So how would we, as a multidi...

Would you offer immunotherapy after chemoradiotherapy for Stage III lung cancer given results of PACIFIC Trial?

3
2 Answers

Mednet Member
Mednet Member
Medical Oncology · Albert Einstein College of Medicine at Montefiore Medical Center

In light of the comments by Professor Vansteenkinste comparing the ESMO 2017 plenary session incorporating the PACIFIC study results as a “tsunami” in the footsteps of last year’s ESMO lung cancer “earthquake” presentations, an appropriate title to this question might be- should we let the” floodgat...

How do you compensate for treatment breaks >1 week in patients with NSCLC on concurrent chemoradiation?

2
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Montefiore Einstein Comprehensive Cancer Center

Classical radiobiology dictates that some sort of treatment intensification could be indicated for a locally advanced NSCLC patient whose chemoradiotherapy course is interrupted. Though many of my patients have treatment interruptions for a variety of reasons, I almost never increase the total presc...

Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?

4
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arizona

Radiation necrosis (RN) following SRS can occur at variable intervals of time following treatment, usually occurring 9-18 months later. The preferred first line of approach is usually steroids, as done in this case. I usually look at the MRI-Flair images and determine the dose of dexamethasone depen...

Is there a role for definitive radiotherapy in patients with de-novo metastatic cervical cancer after achieving complete response with chemo-immunotherapy per KEYNOTE-826?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

We don't know the true impact of local treatment or the durability of CR from chemo IO response. In situations like this, I have sometimes done brachy alone to treat the primary site for local control and prevent future symptomatology.

How would you approach a patient with plasmablastic lymphoma of the nasal cavity s/p excisional biopsy to positive margins who is not a candidate for systemic therapy?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

Plasmablastic lymphoma is a particularly aggressive non-Hodgkin lymphoma. It commonly arises in the H&N region, often in patients who are immunosuppressed for one reason or another. Most patients present with advanced disease.For patients with stage I-II disease, a combined modality therapy approach...

What volumes do you treat for ISRT for extranodal DLBCL?

1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

It is important to remember that ISRT, for both Hodgkin and non-Hodgkin lymphoma, consists of a set of principles that can be used to design rational radiation fields in the context of modern treatment planning. In general, only sites of original involvement are treated when patients also receive, a...

When utilizing ISRT for Hodgkin lymphoma, what volumetric expansions (ITV and PTV) are appropriate on top of the CTV that includes the original pre-systemic therapy disease?

1
1 Answers

Mednet Member
Mednet Member
Radiation Oncology · Duke University Medical Center

First, it is important to realize that involved-site radiation therapy (ISRT) for Hodgkin lymphoma is not a formulaic approach to field design. It requires careful evaluation of pre-chemotherapy imaging, fusing these with post-chemotherapy planning CT scans for optimal target delineation, evaluating...

How do you approach radiotherapy planning when there is no identifiable prostate tissue after HIFU or TURP?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · UC San Diego

I am not sure why there would be no identifiable prostate tissue. There was apparently enough to detect cancer on biopsy, which is ultrasound-guided, so someone must have seen prostate tissue at that time. I suggest getting a high-quality MRI and a careful review. I would also order a PSMA PET for r...